Retatrutide vs Semaglutide vs Tirzepatide: Receptor Pharmacology Compared

Receptor coverage

The defining difference is which receptors of the class B GPCR family each peptide activates.

• Semaglutide — a GLP-1 receptor agonist. A GLP-1(7-37) analogue with an Aib8 substitution and a C18 fatty-diacid side chain for albumin binding.
• Tirzepatide — a dual GIP and GLP-1 receptor agonist. A 39-amino-acid peptide based on the GIP sequence, with a C20 fatty-diacid moiety; it shows a GIP-biased receptor profile in binding assays.
• Retatrutide — a GIP, GLP-1 and glucagon receptor tri-agonist. A 39-amino-acid peptide with a C20 fatty-diacid, balanced across the three receptors in reported in-vitro potency data.

How the differences show up in the laboratory

Because each peptide engages a different receptor set, they are not interchangeable in comparative assays. cAMP accumulation, β-arrestin recruitment and receptor-internalisation assays in cell lines expressing GLP-1R, GIPR or GCGR are the standard ways to characterise their selectivity, and the glucagon-receptor arm of Retatrutide requires a GCGR-expressing model that GLP-1-only studies do not.

Choosing a comparator

A single-receptor compound (Semaglutide) is the usual baseline arm; a dual agonist (Tirzepatide) isolates the contribution of GIP receptor activation; a tri-agonist (Retatrutide) adds glucagon-receptor signalling. Which pen suits an experiment depends on which receptor combination the protocol is designed to interrogate.

Research use only

Body Pharm supplies Retatrutide and Tirzepatide as sealed, pre-filled multi-dose research pens with a batch-specific Certificate of Analysis. Every product is supplied strictly for laboratory research and is not for human or veterinary use. No dosing information is provided.